Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by GCS.
Page 9: 1 2 3 4 5 6 7 8 9
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
2401 | 5 | 9 | 2295 2003 ACTA HAEMATOLOGICA 109(3):153-155 Tsiara S; Chaidos A; Kapsali H; Tzouvara E; Bourantas KL Thalidomide administration for the treatment of resistant plasma cell leukemia | 0 | 0 |
2402 | 8 | 11 | 2296 2003 ADAMANTIADES-BEHCET'S DISEASE 528:585-589 Sohn S; Lee ES; Lee SI; Kim YA; Kwon HJ; Bang D; Lei S Therapeutic effect of thalidomide through cytokine and chemokine regulation in herpes simplex virus-induced Behcet's disease-like animal model | 0 | 0 |
2403 | 56 | 65 | 2299 2003 AMERICAN JOURNAL OF CLINICAL DERMATOLOGY 4(6):379-387 Pelle MT; Werth VP Thalidomide in cutaneous lupus erythematosus | 0 | 0 |
2404 | 3 | 10 | 2302 2003 AMERICAN JOURNAL OF HEMATOLOGY 74(3):205-207 Barton JC Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia | 0 | 0 |
2405 | 1 | 5 | 2303 2003 AMERICAN JOURNAL OF HEMATOLOGY 74(4):290-291 Gomez-Rangel JD; Ruiz-Delgadoz GJ; Ruiz-Arguelles GJ Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myelorna receiving thalidomide | 0 | 0 |
2406 | 0 | 0 | 2304 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):197-197 Kohlhase J; Schubert L; Liebers M; Hennekam RCM; Rauch A; Becker K; Mohammed SN; Wright M; Hannibal MC; Newbury-Ecob R; Reardon W SALL4 mutations result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, Acro-Reno-Ocular syndrome and patients previously reported to represent Thalidomide Embryopathy. | 0 | 0 |
2407 | 0 | 0 | 2305 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):286-286 Pan P; Omlin K; Rosenthal J; Padilla O; Stadecker M; Demmer L A case of Restrictive Dermopathy with survival beyond the neonatal period and novel experience with thalidomide therapy | 0 | 0 |
2408 | 1 | 10 | 2306 2003 AMERICAN JOURNAL OF MEDICINE 115(4):332-334 Staak JO; Glossmann JP; Esser JM; Diehl V; Mietz H; Josting A Thalidomide for systemic capillary leak syndrome | 0 | 0 |
2409 | 8 | 13 | 2307 2003 AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS 10(4):257-261 Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Witzig TE; Fonseca R; Lust JA; Greipp PR; Kyle RA; Gertz MA Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis | 0 | 0 |
2410 | 6 | 6 | 2308 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(4):489-489 Schmutz JL; Barbaud A; Trechot P Thalidomide and thrombosis | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2411 | 4 | 19 | 2309 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(12):1109-1112 Macario-Barrel A; Balguerie X; Joly P Treatment of erosive oral lichen planus with thalidomide | 0 | 0 |
2412 | 1 | 1 | 2310 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(12):1187-1187 Schmutz JL; Barbaud A; Trechot P Thalidomide: the first case with gynecomastia | 0 | 0 |
2413 | 2 | 5 | 2311 2003 ANNALS OF HEMATOLOGY 82(4):262-262 Ribatti A; Vacca A On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma | 0 | 0 |
2414 | 27 | 37 | 2312 2003 ANNALS OF HEMATOLOGY 82(9):558-564 Huang SY; Tang JL; Yao M; Ko BS; Hong RL; Tsai W; Wang CH; Tien HF; Shen MC; Chen YC Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma | 0 | 0 |
2415 | 9 | 33 | 2313 2003 ANNALS OF HEMATOLOGY 82(10):654-659 Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IGD; Martin H; Hoelzer D; Ho AD; Lokhorst HM Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients | 0 | 0 |
2416 | 10 | 33 | 2315 2003 ANNALS OF PHARMACOTHERAPY 37(4):571-576 Thompson JL; Hansen LA Thalidomide dosing in patients with relapsed or refractory multiple myelorna | 0 | 0 |
2417 | 12 | 27 | 2319 2003 ANTICANCER RESEARCH 23(3B):2405-2411 Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice | 0 | 0 |
2418 | 6 | 17 | 2320 2003 ANTICANCER RESEARCH 23(3B):2481-2487 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells | 0 | 0 |
2419 | 7 | 17 | 2322 2003 APMIS 111:113-116 Chew M; Zhou J; Daugherty A; Eriksson T; Ellermann-Eriksen S; Hansen PR; Falk E Thalidomide inhibits early atherogenesis in apoE-deficient mice | 0 | 0 |
2420 | 10 | 16 | 2323 2003 ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX 96(10):1006-1010 Jego C; Barbou F; Laurent P; Gisserot O; Cellarier G; Bonal J; Bouchiat C; Landais C; de Jaureguiberry JP; Dussarat GV Left atrial thrombus in the course of multiple myeloma treated with thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2421 | 16 | 25 | 2325 2003 ARCHIVES OF DERMATOLOGY 139(2):136-138 Thomas P; Walchner M; Ghoreschi K; Rocken M Successful treatment of granulomatous cheilitis with thalidomide | 0 | 0 |
2422 | 2 | 7 | 2326 2003 ARCHIVES OF INTERNAL MEDICINE 163(12):1487-1488 Schwartzman R; Chevlen E; Bengtson K Thalidomide has activity in treating complex regional pain syndrome | 0 | 0 |
2423 | 1 | 1 | 2327 2003 ARCHIVES OF INTERNAL MEDICINE 163(12):1488-1488 Rajkumar SV; Fonseca R; Witzig TE Thalidomide has activity in treating complex regional pain syndrome - Reply | 0 | 0 |
2424 | 0 | 4 | 2328 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(5):240-240 Garcia BD; Gafas AD; Alvarez MJF Lung toxicity due to thalidomide | 0 | 0 |
2425 | 1 | 5 | 2329 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(6):286-286 Valero FC Lung toxicity due to thalidomide | 0 | 0 |
2426 | 0 | 0 | 2330 2003 ARTHRITIS AND RHEUMATISM 48(9):S92-S92 Schechter SJ; Sundel R; Oliveira SK; Huttenlocher A; Onel K; Lehman TJA Thalidomide for severe systemic onset JIA. | 0 | 0 |
2427 | 0 | 0 | 2331 2003 ARTHRITIS AND RHEUMATISM 48(9):S587-S587 Doria A; Briani C; Zara G; Rondinone R; Ermani M; Della Libera S; Ghirardello A; Zampieri S; Tedesco S Prospective study on thalidomide-induced peripheral neuropathy in SLE. | 0 | 0 |
2428 | 0 | 0 | 2332 2003 ARTHRITIS AND RHEUMATISM 48(9):S588-S589 Vazquez-Cobian LB; Onel KB; Lehman TJA Thalidomide in systemic lupus erythematosus. | 0 | 0 |
2429 | 0 | 0 | 2333 2003 ARTHRITIS AND RHEUMATISM 48(9):S617-S617 Efthimiou P; Rosenkranz ME; Mackenzie R; Adler R; Paget SA IVIG and thalidomide combination is an effective novel therapy for scleromyxedema. | 0 | 0 |
2430 | 0 | 0 | 2334 2003 ATHEROSCLEROSIS SUPPLEMENTS 4(2):28-28 Park SJ Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2431 | 0 | 0 | 2335 2003 BIOFUTUR (238):42-43 Knoll M The return of thalidomide | 0 | 0 |
2432 | 0 | 0 | 2337 2003 BIOTECHNOLOGY LAW REPORT 22(2):120-120 [Anon] Celgene, EntreMed agree to license for thalidomide analog - Companies will drop their infringement suits | 0 | 0 |
2433 | 0 | 4 | 2339 2003 BLOOD 102(1):2-3 Hussein MA Thalidomide, age, and future use in multiple myeloma | 0 | 0 |
2434 | 0 | 0 | 2341 2003 BLOOD 102(11):33A-33A Mesa RA; Elliott MA; Faoro L; Tefferi A Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: Long term outcome analysis of 2 prospective trials. | 0 | 0 |
2435 | 0 | 0 | 2342 2003 BLOOD 102(11):56B-56B Ballester G; Ballester O; Daitch L; Kutlar A Response to thalidomide therapy in multicentric Castleman's disease. | 0 | 0 |
2436 | 0 | 0 | 2343 2003 BLOOD 102(11):148A-148A Palumbo A; Bertola A; Musto P; Nunzi M; De Stefano V; Callea V; Rotoli B; Petti MC; Caravita T; Lauta VM; Patti C; Bringhen S; Cavallo F; Falco P; Carella AM; Liberati AM; Boccadoro M Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. | 0 | 0 |
2437 | 0 | 0 | 2344 2003 BLOOD 102(11):148A-149A Dimopoulos MA; Anagnostopoulos A; Hamilos G; Zomas A; Efstathiou E; Grigoraki V; Poziopoulos C; Gika D; Xilouri I; Zorzou MP; Anagnostopoulos N Pulsed cyclophosphamide, thalidomide and dexamethasone: Long term follow-up of an oral regimen for previously treated patients with multiple myeloma. | 0 | 0 |
2438 | 0 | 0 | 2345 2003 BLOOD 102(11):149B-149B Moutouh-de Parseval LA; Glezer E; Corral L; Muller G; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cells developmental pathway. | 0 | 0 |
2439 | 0 | 0 | 2347 2003 BLOOD 102(11):237A-237A Agrawal NR; Hussein MA; Elson P; Karam MA; Reed J; Srkalovic G Pegylated Doxorubicin(D), Vineristine(V), reduced frequency Dexamethasone(D) and Thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. | 0 | 0 |
2440 | 0 | 0 | 2348 2003 BLOOD 102(11):237A-237A Niesvizky R; Pekle K; Lyons L; Pearse RN; Bergsagel PL; Schuster MW; Cho HJ; Leonard JP; Coleman M Dexamethsone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin(TM)) on response rate. interim results of a prospective, sequential, randomized trial. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2441 | 0 | 0 | 2349 2003 BLOOD 102(11):259B-259B Cooper BW; Koc ON; Lazarus HM; Laughlin MJ; Myerson HJ; Creger RJ Phase II study of fludarabine, carboplatin, topotecan, and thalidomide for patients with acute myelogenous leukemia and advanced myelodysplastic syndromes. | 0 | 0 |
2442 | 0 | 0 | 2350 2003 BLOOD 102(11):327B-328B Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Carella AM Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes. | 0 | 0 |
2443 | 0 | 0 | 2351 2003 BLOOD 102(11):330B-330B Leb LV; Becker P; Brettler D; Church AA; Khanani SA; Rooney JJ; Seidler CW; Yang J; Woda B The potentiating effect of low dose thalidomide given in combination with epoetin alfa in patients with myelodysplastic syndrome (MDS) having low International Prognostic Scoring Systems (IPSS). | 0 | 0 |
2444 | 0 | 0 | 2352 2003 BLOOD 102(11):353B-353B Chanan-Khan AA; Stein L; David S; Takeshita K; Platt J; Miller K; Fallon A; Czuczman MS; Hawthorn L Thalidomide (T) induced in vivo changes in gene expression profile (GEP) of malignant chronic lymphocytic leukemia (CLL) cells. | 0 | 0 |
2445 | 0 | 0 | 2353 2003 BLOOD 102(11):359B-359B Kay N; Geyer S; Yaqoob I; Phyliky R; Kutteh L; Li CY Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) study. | 0 | 0 |
2446 | 0 | 0 | 2354 2003 BLOOD 102(11):366B-367B Okikawa Y; Sakai A; Kuroda Y; Katayama Y; Takimoto Y; Okita H; Kimura A Analysis of the maturity of myeloma cells (plasma cells) is useful to select effective chemotherapy including thalidomide and to predict the progressive disease. | 0 | 0 |
2447 | 0 | 0 | 2355 2003 BLOOD 102(11):378B-378B Agrawal NR; Srkalovic G; Sup S; Hsi ED; Elson P; Hussein MA Impact of pegylated doxorubicin(D), vincristine(V), reduced frequency dexamethasone(D) and thalidomide(T) {DVd-T} on bone marrow microvessel density (MVD) in newly diagnosed multiple myeloma (MM) patients (pts). | 0 | 0 |
2448 | 0 | 0 | 2356 2003 BLOOD 102(11):380B-380B Myers B; Russell NH; McMillan AK Use of a novel combination chemotherapy for AL-amyloidosis: Cyclophosphamide, thalidomide and dexamethasone - Serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. | 0 | 0 |
2449 | 0 | 0 | 2357 2003 BLOOD 102(11):381B-381B Breitkreutz I; Cremer FW; Benner A; Moehler T; Fruehauf S; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide administration. | 0 | 0 |
2450 | 0 | 0 | 2358 2003 BLOOD 102(11):381B-381B Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Barulli S; Capelli D; Rupoli S; Leoni P Combination therapy with Caelyx, dexamethasone and thalidomide (CDT) for multiple myeloma (MM): Preliminary results of a phase II-III study. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2451 | 0 | 0 | 2360 2003 BLOOD 102(11):382B-382B Novoselac AV; Reddy S; Ohsumi F; Sherman RE; Samaha S Acute myeloid leukemia in patient with multiple myeloma treated with thalidomide. | 0 | 0 |
2452 | 0 | 0 | 2361 2003 BLOOD 102(11):382B-383B Caravita T; Siniscalchi A; Niscola P; Santinelli S; Buccisano F; Montanaro M; De Fabritiis P; Amadori S Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma. | 0 | 0 |
2453 | 0 | 0 | 2362 2003 BLOOD 102(11):383B-383B Guglielmelli T; Capella S; Mattioli G; Guerrasio A; Saglio G Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma. | 0 | 0 |
2454 | 0 | 0 | 2363 2003 BLOOD 102(11):383B-384B Spencer A; Roberts A; Bailey M; Schran H; Lynch K No evidence for an adverse interaction between zoledronic acid and thalidomide: Preliminary safety analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) MM6 myeloma trial. | 0 | 0 |
2455 | 0 | 0 | 2364 2003 BLOOD 102(11):385B-385B Di Raimondo F; Pennisi A; Buglio D; Fiumara P; Palumbo GA; Giustolisi R Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma. | 0 | 0 |
2456 | 0 | 0 | 2365 2003 BLOOD 102(11):385B-386B Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Combined thalidomide-dexametasone and zoledronic acid induce a reduction of bone resorption markers in newly diagnosed multiple myeloma patients. | 0 | 0 |
2457 | 0 | 0 | 2366 2003 BLOOD 102(11):386B-386B Kyriakou CA; D'Sa SP; Flory A; Hanslip J; Peggs KS; Yong KL Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma. | 0 | 0 |
2458 | 0 | 0 | 2367 2003 BLOOD 102(11):387B-387B Kumar S; Witzig TE; Wellik L; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Kyle RA; Gertz MA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. | 0 | 0 |
2459 | 0 | 0 | 2368 2003 BLOOD 102(11):389B-389B Chanan-Khan AA; Miller K; Srinivasan S; David S; McCarthy P; Alam A; Bernstein ZP; Czuczman MS Velcade (Vel), Doxil (R) (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM). | 0 | 0 |
2460 | 0 | 0 | 2369 2003 BLOOD 102(11):390B-390B Oyan B; Koc Y; Kars A; Turker A; Tekuzman G; Kansu E Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2461 | 0 | 0 | 2370 2003 BLOOD 102(11):443A-443A El-Sherbiny YM; Davies FE; Cook G; Johnson RJ; Cullen MJ; Sah A; Rawstron AC; Richards SJ; Morgan GJ NK cell repertoire in myeloma and the impact of thalidomide. | 0 | 0 |
2462 | 0 | 0 | 2371 2003 BLOOD 102(11):448A-448A Cavo M; Zamagni E; Tosi P; Cellini C; de Vivo A; Cangini D; Tonelli M; Testoni N; Grafone T; Tacchetti P; Soverini S; Terragna C; Tura S; Baccarani M Primary therapy with thalidomide and dexamethasone in preparation to autologous transplantation for multiple myeloma. | 0 | 0 |
2463 | 0 | 0 | 2372 2003 BLOOD 102(11):449A-449A Patten PE; Ahsan G; Kazmi M; Fields PA; Chick GW; Jones RR; Bradwell AR; Schey SA The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047). | 0 | 0 |
2464 | 0 | 0 | 2373 2003 BLOOD 102(11):450A-450A Zervas K; Dimopoulos MA; Hatziharisi E; Anagnostopoulos A; Papaioannou M; Mitsouli C; Panagiotidis P; Korantzis L; Tzilianos M; Maniatis A Primary treatment of mutiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. | 0 | 0 |
2465 | 0 | 0 | 2374 2003 BLOOD 102(11):450A-451A Comenzo RL; Hassoun H; Reich L; Klimek V; Kewalramani T; Dhodapkar M; Drake L; Hedvat C; Teruya-Feldstein J; Fleisher M; Filippa DA; Nimer SD Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma. | 0 | 0 |
2466 | 0 | 0 | 2376 2003 BLOOD 102(11):453A-454A Abonour R; Ganjoo K; Fausel C; Yiannoutsos C; Juliar BE; Wood LL; Smith GG; Walker P; Cripe LD A phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma, a Hoosier Oncology Group (HOG) trial: HEM01-21. | 0 | 0 |
2467 | 0 | 0 | 2377 2003 BLOOD 102(11):454A-454A Anaissie EJ; Jacobson J; Fassas AB; Zangari M; Thertulien R; VanRhee F; Talamo G; Tricot G; Wendling C; Davis CK; Hollmig K; Barlogie B Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. | 0 | 0 |
2468 | 0 | 0 | 2378 2003 BLOOD 102(11):454A-454A Anagnostopoulos A; Efstathiou E; Hamilos G; Zorzou MP; Kastritis E; Dimopoulos MA Patterns of progression in myeloma patients treated with thalidomide-based regimens: High incidence of extramedullary progression without serologic relapse. | 0 | 0 |
2469 | 0 | 0 | 2379 2003 BLOOD 102(11):456B-456B Yakoub-agha I; Mohty M; Attal M; Marit G; Bulabois CE; Sotto JJ; Gratecos N; Rio B; Vernant JP; Dib M; Garban F; Cahn JY; Jouet JP; Facon T Thalidomide (THAL) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT). | 0 | 0 |
2470 | 0 | 0 | 2380 2003 BLOOD 102(11):489B-490B Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2471 | 0 | 0 | 2381 2003 BLOOD 102(11):490B-490B Castro J; Davila J; Perez S; Flores L; Lopez A; Roman A; Pacheco E; Fernandex A; Fradera J; Garcia R; Merle S; Velez-Garcia E High dose chemotherapy (HDC) with autologous transplant (AT) followed by thalidomide (T) as maintenance in patients (P) with multiple myeloma (MM). | 0 | 0 |
2472 | 0 | 0 | 2382 2003 BLOOD 102(11):554A-554A Biemond BJ; Havik SR; Meijers JCM; Levi MM; Van Oers MHJ Strong thrombogenic activity of the combined administration of thalidomide and doxorubicin in experimental thrombosis in the rabbit. | 0 | 0 |
2473 | 0 | 0 | 2383 2003 BLOOD 102(11):675A-675A Chanan-Khan AA; Fallon A; Miller K; Bernstein ZP; Hernandez F; Alam A; McCarthy P; Mohr A; Czuczman MS Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial. | 0 | 0 |
2474 | 0 | 0 | 2384 2003 BLOOD 102(11):684A-684A Badros AZ; Ratterree B; Natt S; Rapoport AP; Zeldis JB; Frankel SR; Meisenberg B; Takebe N; Zwiebel JA; Zhang B; Fenton R Phase I/II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma. | 0 | 0 |
2475 | 0 | 0 | 2385 2003 BLOOD 102(11):686A-686A Hovenga S; Daenen SMGJ; de Wolf JTM; van Imhoff GW; Kluin-Nelemans HC; Vellenga E Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study. | 0 | 0 |
2476 | 0 | 0 | 2386 2003 BLOOD 102(11):687A-687A Zangari M; Barlogie B; Lee CK; Kang SH; Fassas A; Thertulien R; Van Rhee F; Talamo G; Burns M; Anaissie EJ; Tricot G; Jacobson J Increment in bone phophatase (ALP) in myeloma patients during treatment with velcade, thalidomide and dexamethasome (VTD) is a strong predictor for response. | 0 | 0 |
2477 | 0 | 0 | 2387 2003 BLOOD 102(11):687A-687A Latif T; Elson P; Karam MA; Reed J; Tahir K; Srkalovic G; Hussein MA Incidence of renal impairment (RI) in multiple myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy. | 0 | 0 |
2478 | 0 | 0 | 2388 2003 BLOOD 102(11):689A-689A Hattori Y; Kakimoto T; Okamoto S; Iguchi T; Morita K; Tanigawara Y; Ikeda Y Plasma concentration of thalidomide and clinical efficacy in patients with multiple myeloma. | 0 | 0 |
2479 | 0 | 0 | 2389 2003 BLOOD 102(11):691A-691A Feyler S; Jackson G; Rawstron A; El-Sherbiny YM; Snowden JA; Johnson RJ Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. | 0 | 0 |
2480 | 0 | 0 | 2390 2003 BLOOD 102(11):691A-692A Hoyer B; Fenk R; Steidl U; Kondakci M; Germing U; Haas R; Kobbe G Single agent thalidomide for treatment of first relapse following high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2481 | 0 | 0 | 2391 2003 BLOOD 102(11):692A-692A Moehler T; Hillengass J; Gerull S; Benner A; Schlenzka J; Neben K; Egerer G; Schaefer H; Goerner M; He AD Thalidomide (T) and CED chemotherapy followed by stem cell transplantation for poor prognosis multiple myeloma. | 0 | 0 |
2482 | 0 | 0 | 2392 2003 BLOOD 102(11):829A-830A Lentzsch S; Koh KR; Stirling D; Zenke M; Dorken B Immunomodulatory derivative of thalidomide (IMiD CC-4047) determine the lineage commitment of hematopoietic progenitors by down regulation of GATA-1 and modulation of cytokine secretion. | 0 | 0 |
2483 | 0 | 0 | 2393 2003 BLOOD 102(11):903A-903A Mitsiades CS; Mitsiades N; McMullan CJ; Poulaki V; Shringarpure R; Hideshima T; Chauhan D; Treon SP; Richardson PG; Munshi NC; Joseph M; Libermann TA; Anderson KC Immunomodulatory thalidomide derivatives have activity against tumor cells from Waldenstrom's macroglobulinemia. | 0 | 0 |
2484 | 0 | 0 | 2394 2003 BLOOD 102(11):923A-924A Elliott MA; Geyer SM; Camoriano JK; Kahanic SP; Alexander SJ; Medgyesy DC; Li CY; Tefferi A Low dose thalidomide (Td) treatment in myelofibrosis with myeloid metaplasia (MMM): An NCCTG study. | 0 | 0 |
2485 | 0 | 0 | 2395 2003 BLOOD 102(11):938A-938A Anagnostopoulos A; Zervas K; Zomas A; Pouli A; Hamilos G; Anagnostopoulos N; Dimopoulos MA The International Prognostic Index (IPI) is predictive for survival in refractory or relapsed myeloma patients treated with thalidomide-based regimens. | 0 | 0 |
2486 | 0 | 0 | 2396 2003 BLOOD 102(11):984A-984A Sahebi F; Somlo G; Kogut NM; Falk PM; Spielberger R; Parker PM; Krishnan A; Frankel P; Kosobayashi N; Forman SJ Feasibility and toxicity of maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma | 0 | 0 |
2487 | 0 | 0 | 2397 2003 BLOOD 102(11):985A-986A Somlo G; Yamamoto N; Carter N; O'Donnell M; Snyder D; Sahebi F; Krishnan A; Fung H; Stein A; Spielberger R; Schriber J; Alvarnas J; Chow W; Nademance A; Jasmine Z; Stephen F High complete response rate is associated with improved progression-free and overall survival in 104 patients with multiple myeloma, treated with tandem cycle high-dose melphalan and busulfan/cytoxan, and maintenance interferon alpha-2 (IF) with, or without thalidomide (Thai) | 0 | 0 |
2488 | 0 | 0 | 2398 2003 BONE MARROW TRANSPLANTATION 31:S76-S77 Tueger S; Chen F; Ahsan G; Andrews V; Kazmi M; Madrigal J; Schey S Thalidomide-induced remission of refractory diffuse large B-cell lymphoma post-allogeneic SCT - a result of modulation of CTL function? | 0 | 0 |
2489 | 0 | 0 | 2399 2003 BONE MARROW TRANSPLANTATION 31:S78-S79 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fili C; Cerno M; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
2490 | 2 | 6 | 2400 2003 BONE MARROW TRANSPLANTATION 31(11):1065-1065 Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2491 | 0 | 1 | 2401 2003 BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
2492 | 6 | 6 | 2403 2003 BONE MARROW TRANSPLANTATION 32(3):343-343 Milone JH; Prates V; Bordone J; Napal J; Garcia C Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD | 0 | 0 |
2493 | 0 | 0 | 2405 2003 BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
2494 | 0 | 0 | 2406 2003 BRITISH JOURNAL OF CANCER 88:S46-S46 Malpas J; Chaplin T; Sanmugathasan A; Liu W In vitro activity of S-thalidomide against multiple myeloma cells: A gene and protein expression profile. | 0 | 0 |
2495 | 4 | 9 | 2408 2003 BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
2496 | 5 | 11 | 2409 2003 BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
2497 | 0 | 0 | 2410 2003 BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
2498 | 11 | 14 | 2411 2003 BRITISH JOURNAL OF DERMATOLOGY 149(2):432-433 Dobson CM; Parslew RA Exacerbation of psoriasis by thalidomide in Behcet's syndrome | 0 | 0 |
2499 | 9 | 20 | 2420 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):436-441 Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia | 0 | 0 |
2500 | 1 | 3 | 2422 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):747-748 Mileshkin L; Prince HM; Seymour JF; Biagi JJ Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2501 | 0 | 3 | 2423 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):748-748 Luminari S; Federico M; Baldini L Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. | 0 | 0 |
2502 | 0 | 1 | 2424 2003 BRITISH MEDICAL JOURNAL 327(7418):767-767 Burgermeister J Head of German medicines body likens HRT to thalidomide | 0 | 0 |
2503 | 5 | 27 | 2426 2003 CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
2504 | 0 | 0 | 2427 2003 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 12(11):1288S-1288S Hsu C; Chen HN; Chen LT; Wu CY; Hsieh FJ; Cheng AL Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma. | 0 | 0 |
2505 | 5 | 39 | 2430 2003 CELLULAR AND MOLECULAR BIOLOGY 49(7):1117-1124 Ezell TN; Maloney N; Githua JW; Taylor LD Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells | 0 | 0 |
2506 | 0 | 0 | 2432 2003 CIRCULATION 108(17):170-170 Kirchmair R; Murayama T; Rittig K; Tietz A; Walter D; Schratzberger P; Weinberg DH; Ropper AH; Isner JM Therapeutic angiogenesis inhibits and rescues chemotherapy induced peripheral neuropathy: Taxol, cisplatin and thalidomide induced injury vasa nervorum is ameliorated by VEGF gene therapy | 0 | 0 |
2507 | 4 | 12 | 2433 2003 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21(2):272-272 Meaux-Ruault N; Magy N; Gil H; Dupond JL Efficacy of thalidomide in refractory adult Still's disease: A new case report | 0 | 0 |
2508 | 0 | 0 | 2435 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Ching LM; Baguley BC; Kestell P; Palmer BD; Lu J Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. - Reply | 0 | 0 |
2509 | 8 | 8 | 2436 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Zhou SF Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. | 0 | 0 |
2510 | 0 | 0 | 2437 2003 CLINICAL CANCER RESEARCH 9(16):6150S-6150S Baas P; Haringhuizen A; Boogerd W; Dalesio O; Van Zandwijk N Thalidomide in malignant pleural mesothelioma: Results of a phase II study. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2511 | 9 | 21 | 2439 2003 CLINICAL LYMPHOMA 3(4):247-248 Blade J; Rosinol L Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies | 0 | 0 |
2512 | 0 | 0 | 2441 2003 CLINICAL PHARMACOLOGY & THERAPEUTICS 73(2):P55-P55 Gordon SM; Wahl SM; Picco C; Dionne RA Safety and tolerability and absorption of topical thalidomide. | 0 | 0 |
2513 | 2 | 3 | 2447 2003 DIABETES CARE 26(4):1322-1323 Pathak RD; Jayaraj K; Blonde L Thalidomide-associated hyperglycemia and diabetes - Case report and review of literature | 0 | 0 |
2514 | 0 | 0 | 2450 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Miyata M CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation - Reply | 0 | 0 |
2515 | 5 | 10 | 2451 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Zhou SF CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation | 0 | 0 |
2516 | 0 | 0 | 2452 2003 EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
2517 | 1 | 6 | 2454 2003 EUROPEAN JOURNAL OF HAEMATOLOGY 70(3):198-199 Vicari P; Ribas C; Sampaio M; Arantes AM; Yamamoto M; Reis JB; Segreto RA; Bordin JO; Colleoni GWB Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? | 0 | 0 |
2518 | 0 | 0 | 2455 2003 EXPERIMENTAL HEMATOLOGY 31(7):198-198 Moutouh-De Parseval L; Glezer E; Corral L; Galliher A; Wu J; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cell developmental pathways | 0 | 0 |
2519 | 0 | 0 | 2457 2003 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
2520 | 0 | 0 | 2458 2003 GASTROENTEROLOGY 124(4):A10-A10 Jin SH; Kim WH; Kim TI; Yang KM; Shin SK; Lee SK; Park SJ; Choi CH; Lee WJ Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2521 | 0 | 0 | 2459 2003 GASTROENTEROLOGY 124(4):A336-A336 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on NF-R activity and TNF-production stimulated with lipopolysaccharide in a human colonic epithelial cell line ka | 0 | 0 |
2522 | 0 | 0 | 2460 2003 GASTROENTEROLOGY 124(4):A525-A525 Gupta P; Andrew H; Kirschner BS Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab | 0 | 0 |
2523 | 3 | 10 | 2461 2003 HAEMATOLOGICA 88(5):597-599 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
2524 | 4 | 10 | 2462 2003 HAEMATOLOGICA 88(8):958-960 Corso A; Lorenzi A; Zapposodi P; Invernizzi R; Vanelli L; Lazzarino M Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma | 0 | 0 |
2525 | 6 | 15 | 2464 2003 INTERNAL MEDICINE 42(7):550-551 Dan K Thalidomide as a targeted therapy for multiple myeloma | 0 | 0 |
2526 | 16 | 42 | 2466 2003 INTERNATIONAL IMMUNOPHARMACOLOGY 3(10-11):1447-1456 Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study | 0 | 0 |
2527 | 12 | 39 | 2467 2003 INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
2528 | 7 | 20 | 2469 2003 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11(6):785-790 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Effects of thalidomide on the expression of angiogenesis growth factors in human A(549) lung adenocarcinoma cells | 0 | 0 |
2529 | 13 | 23 | 2471 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 23(6):1651-1655 Kaicker S; McCrudden KW; Beck L; New T; Huang JZ; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma | 0 | 0 |
2530 | 17 | 32 | 2472 2003 INVESTIGATIONAL NEW DRUGS 21(3):359-366 Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Dalla Costa T; Di Leone LP; Schwartsmann G Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2531 | 4 | 9 | 2473 2003 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
2532 | 0 | 0 | 2474 2003 JOURNAL OF BONE AND MINERAL RESEARCH 18:S310-S310 Bose N; Bergemann H; Westendorf JJ; Rajkumar SV; Masellis AM Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment. | 0 | 0 |
2533 | 59 | 70 | 2475 2003 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
2534 | 7 | 12 | 2484 2003 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22(4):129-133 Bernardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma | 0 | 0 |
2535 | 10 | 16 | 2485 2003 JOURNAL OF INFECTION 47(3):251-255 Roberts MTM; Mendelson M; Meyer P; Carmichael A; Lever AML The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports | 0 | 0 |
2536 | 19 | 40 | 2486 2003 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
2537 | 11 | 25 | 2490 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(18):3793-3799 Luzzio FA; Mayorov AV; Ng SSW; Kruger EA; Figg WD Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF alpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine | 0 | 0 |
2538 | 10 | 26 | 2492 2003 JOURNAL OF NEURO-ONCOLOGY 64(3):193-201 Gelati M; Corsini E; Frigerio S; Pollo B; Broggi G; Croci D; Silvani A; Boiardi A; Salmaggi A Effects of thalidomide on parameters involved in angiogenesis: an in vitro study | 0 | 0 |
2539 | 4 | 4 | 2493 2003 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 37(4):522-522 Ahmed M; El-Hadi S; Jenkins HR Thalidomide in Crohn disease and the risk of peripheral neuropathy | 0 | 0 |
2540 | 2 | 5 | 2494 2003 JOURNAL OF PEDIATRICS 143(5):692-694 Yasui K; Misawa Y; Shimizu T; Komiyama A; Kawakami T; Mizoguchi M Thalidomide therapy for juvenile-onset entero-Behcet disease | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2541 | 9 | 12 | 2500 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
2542 | 0 | 0 | 2502 2003 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
2543 | 0 | 0 | 2503 2003 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
2544 | 8 | 12 | 2506 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(12):2691-2692 Arkel YS; Ku DHW; Thurston AL The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)- alpha-stimulated cells | 0 | 0 |
2545 | 0 | 0 | 2507 2003 JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
2546 | 0 | 0 | 2508 2003 LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
2547 | 0 | 0 | 2509 2003 LANCET ONCOLOGY 4(12):713-713 Habeck M Australia approves thalidomide | 0 | 0 |
2548 | 9 | 20 | 2510 2003 LEPROSY REVIEW 74(3):206-214 Tadesse A; Taye E; Sandoval F; Shannow EJ Thalidomide does not modify the ability of cells in leprosy patients to incorporate [H-3]-thymidine when incubated with M-leprae antigens | 0 | 0 |
2549 | 7 | 32 | 2512 2003 LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
2550 | 10 | 11 | 2519 2003 LEUKEMIA 17(9):1914-1915 Damaj G; Lefrere F; Delarue R; Varet B; Furman R; Hermine O Thalidomide therapy induces response in relapsed mantle cell lymphoma | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2551 | 3 | 8 | 2520 2003 LEUKEMIA 17(10):2056-2057 Dalle JH; Leblond P; Decouvelaere A; Yakoub-Agha I; Preudhomme C; Nelken B; Mazingue F Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL | 0 | 0 |
2552 | 3 | 6 | 2521 2003 LEUKEMIA 17(11):2237-2238 Mehta P; Hussein M Thalidomide as anti-inflammatory therapy for multiple myeloma | 0 | 0 |
2553 | 2 | 6 | 2522 2003 LEUKEMIA 17(11):2238-2238 Rajkumar SV; Witzig TE Thalidomide as anti-inflammatory therapy for multiple myeloma - Reply | 0 | 0 |
2554 | 30 | 38 | 2526 2003 LEUKEMIA & LYMPHOMA 44(7):1141-1146 Flowers MED; Martin PJ Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease | 0 | 0 |
2555 | 19 | 36 | 2528 2003 LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
2556 | 12 | 18 | 2529 2003 LEUKEMIA & LYMPHOMA 44(11):1943-1946 Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Low dose thalidomide in patients with relapsed or refractory multiple myeloma | 0 | 0 |
2557 | 7 | 10 | 2531 2003 LUPUS 12(9):723-724 Tektonidou MG; Vlachoyiannopoulos PG Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus | 0 | 0 |
2558 | 1 | 11 | 2533 2003 MEDICAL HYPOTHESES 60(4):513-514 Namazi MR The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata | 0 | 0 |
2559 | 1 | 2 | 2534 2003 MEDICAL JOURNAL OF AUSTRALIA 178(8):413-413 Elwood JM Thalidomide and cancer? | 0 | 0 |
2560 | 5 | 25 | 2535 2003 MEDICAL ONCOLOGY 20(4):397-401 Fraiman G; Ganti AK; Potti A; Mehdi S Angiosarcoma of the small intestine - Possible role for thalidomide? | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2561 | 1 | 26 | 2545 2003 PEDIATRIC NEUROLOGY 29(2):151-156 Marjanovic BD; Stojanov LM; Zdravkovic DS; Kravljanac RM; Djordjevic MS Rasmussen syndrome and long-term response to thalidomide | 0 | 0 |
2562 | 0 | 0 | 2546 2003 PHARMACOPSYCHIATRY 36(5):263-264 Schuld A; Hinze-Selch D; Haack M; Dalal MA; Himmerich H; Lancel M; Pollmacher T Sleep changes following chlorpromazine, clozapine, olanzapine or thalidomide in healthy subjects - First results from a double-blind, placebocontrolled study | 0 | 0 |
2563 | 43 | 78 | 2548 2003 PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
2564 | 10 | 37 | 2549 2003 PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE 19(6):272-280 Lu KQ; Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways | 0 | 0 |
2565 | 8 | 11 | 2551 2003 PRESSE MEDICALE 32(40):1894-1898 Brocvielle H; Muret P; Plenat E; Kantelip JP; Humbert P Management of a patient receiving thalidomide | 0 | 0 |
2566 | 10 | 48 | 2552 2003 RHEUMATIC DISEASE CLINICS OF NORTH AMERICA 29(3):481-+ Davis JC; Huang F; Maksymowych W New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate | 0 | 0 |
2567 | 43 | 95 | 2553 2003 SCHMERZ 17(3):204-+ Peuckmann V; Strumpf M; Zenz M; Bruera E Novel potential uses of thalidomide in the management of pain? A review of the literature | 0 | 0 |
2568 | 7 | 20 | 2554 2003 SEMINARS IN HEMATOLOGY 40(4):1-2 Barlogie B Introduction: Thalidomide and the IMiDs in multiple myeloma | 0 | 0 |
2569 | 12 | 17 | 2555 2003 SEMINARS IN HEMATOLOGY 40(4):3-7 Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma | 0 | 0 |
2570 | 14 | 23 | 2556 2003 SEMINARS IN HEMATOLOGY 40(4):8-16 Dimopoulos MA; Anagnostopoulos A Thalidomide in relapsed/refractory multiple myeloma: Pivotal trials conducted outside the United States | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2571 | 10 | 33 | 2557 2003 SEMINARS IN HEMATOLOGY 40(4):17-22 Rajkumar SV Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease | 0 | 0 |
2572 | 11 | 14 | 2558 2003 SEMINARS IN HEMATOLOGY 40(4):33-38 Barlogie B Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience | 0 | 0 |
2573 | 8 | 12 | 2561 2003 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 16(2):123-129 Hadgraft J; Goosen C; du Plessis J; Flynn G Predicting the dermal absorption of thalidomide and its derivatives | 0 | 0 |
2574 | 7 | 25 | 2564 2003 WORLD JOURNAL OF SURGERY 27(10):1119-1123 Mall JW; Schwenk W; Philipp AW; Buttemeyer R; Pollmann C Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model | 0 | 0 |
2575 | 12 | 23 | 2565 2003 XENOTRANSPLANTATION 10(5):470-474 Yamamoto S; Cooper DKC An investigation of the effect of thalidomide on anti-gal antibody production in baboons | 0 | 0 |
2576 | 12 | 63 | 2566 2004 ACTA NEUROBIOLOGIAE EXPERIMENTALIS 64(1):1-9 Greig NH; Giordano T; Zhu XX; Yu QS; Perry TA; Holloway HW; Brossi A; Rogers JT; Sambamurti K; Lahiri DK Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases | 0 | 0 |
2577 | 6 | 22 | 2567 2004 ACTA NEUROLOGICA SCANDINAVICA 109(3):188-193 Isoardo G; Bergui M; Durelli L; Barbero P; Boccadoro M; Bertola A; Ciaramitaro P; Palumbo A; Bergamasco B; Cocito D Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features | 0 | 0 |
2578 | 3 | 6 | 2568 2004 ACTA ONCOLOGICA 43(2):215-216 Ribas C; Colleoni G; Almeida M; Duch CR; Ohashi C; Segreto R; Silva MR Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma | 0 | 0 |
2579 | 10 | 60 | 2569 2004 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 19(1):79-88 Austin AS; Mahida YR; Clarke D; Ryder SD; Freeman JG A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis | 0 | 0 |
2580 | 15 | 16 | 2570 2004 AMERICAN JOURNAL OF CARDIOLOGY 93(8):1052-1055 Fahdi IE; Gaddam V; Saucedo JF; Kishan CV; Vyas K; Deneke MG; Razek H; Thorn B; Bissett JK; Anaisse E; Barlogie B; Mehta JL Bradycardia during therapy for multiple myeloma with thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2581 | 2 | 5 | 2571 2004 AMERICAN JOURNAL OF HEMATOLOGY 75(3):176-177 Jung CP; Emmerich B; Goebel FD; Bogner JR Successful treatment of a patient with HIV-associated multicentric castleman disease (MCD) with thalidomide | 0 | 0 |
2582 | 3 | 15 | 2572 2004 AMERICAN JOURNAL OF HEMATOLOGY 76(1):66-68 Sinisalo M; Hietaharju A; Sauranen J; Wirta O Thalidomide in POEMS syndrome: Case report | 0 | 0 |
2583 | 18 | 33 | 2573 2004 AMERICAN JOURNAL OF VETERINARY RESEARCH 65(5):659-664 Farese JR; Fox LE; Detrisac CJ; Van Gilder JA; Roberts SL; Baldwin JA Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice | 0 | 0 |
2584 | 18 | 31 | 2574 2004 ANNALS OF HEMATOLOGY 83(7):467-470 Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide | 0 | 0 |
2585 | 11 | 28 | 2575 2004 ANNALS OF ONCOLOGY 15(1):134-138 Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou A; Mitsouli C; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A; Greek Myeloma Study Grp Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study | 0 | 0 |
2586 | 3 | 3 | 2576 2004 ANNALS OF ONCOLOGY 15(1):176-177 Kasper B; Moehler T; Neben K; Ho AD; Goldschmidt H Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma | 0 | 0 |
2587 | 5 | 5 | 2577 2004 ANNALS OF ONCOLOGY 15(3):537-537 Fuente N; Mane JM; Barcelo R; Munoz A; Perez-Hoyos T; Lopez-Vivanco G Tumor lysis syndrome in a multiple myeloma treated with thalidomide | 0 | 0 |
2588 | 12 | 23 | 2578 2004 ANNALS OF PHARMACOTHERAPY 38(5):808-811 Sayarlioglu M; Kotan MC; Topcu N; Bayram I; Arslanturk H; Gul A Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease | 0 | 0 |
2589 | 29 | 91 | 2579 2004 ANTIOXIDANTS & REDOX SIGNALING 6(1):1-14 Hansen JM; Harris C A novel hypothesis for thalidomide-induced limb teratogenesis: Redox misregulation of the NF-kappa B pathway | 0 | 0 |
2590 | 10 | 44 | 2580 2004 ARCHIVES OF DERMATOLOGY 140(3):277-280 Caradona S; Jacobe H Thalidomide as a potential treatment for scleromyxedema | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2591 | 30 | 47 | 2581 2004 ARCHIVES OF DERMATOLOGY 140(7):845-849 Maurer T; Poncelet A; Berger T Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects - Efficacy and risk of neuropathy | 0 | 0 |
2592 | 11 | 36 | 2582 2004 ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 24(5):885-891 Park SJ; Kim HS; Yang HM; Park KW; Youn SW; Jeon SI; Kim DH; Koo BK; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
2593 | 5 | 11 | 2583 2004 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 51(3):505-506 Pillemer SR; Leakan RA; Sankar V; Manny J; Baum BJ; Smith J; Chaudhry U; Fox PC; Radfar L; Ligier S; Brennan MT Prominent adverse effects of thalidomide in primary Sjogren's syndrome | 0 | 0 |
2594 | 0 | 0 | 2584 2004 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 10(2):73-73 Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
2595 | 12 | 43 | 2585 2004 BIOORGANIC & MEDICINAL CHEMISTRY 12(2):327-336 Capitosti SM; Hansen TP; Brown ML Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer | 0 | 0 |
2596 | 14 | 35 | 2586 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(2):421-425 Perino S; Contino-Pepin C; Satchi-Fainaro R; Butterfield C; Pucci B Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties | 0 | 0 |
2597 | 6 | 31 | 2587 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(16):4141-4145 Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y Phenylhomophthalimide-type NOS inhibitors derived from thalidomide | 0 | 0 |
2598 | 27 | 47 | 2588 2004 BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY 71(1):1-16 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth SL; Hoberman AM Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits | 0 | 0 |
2599 | 0 | 0 | 2589 2004 BONE 34:S97-S97 Spencer A; Roberts A; Bailey M; Schran H; Lynch K Safety and pharmacokinetic analysis of zoledronic acid in a multicentre randomised trial of post-transplant thalidomide maintenance therapy for multiple myeloma | 0 | 0 |
2600 | 0 | 0 | 2590 2004 BONE MARROW TRANSPLANTATION 33:S156-S156 Yakoub-Agha I; Mohty M; Attal M; Marit G; Bulabois C; Sotto JJ; Gratecos N; Rio B; Vernant JP; Facon T; Jouet JP; Intergrp Francophne Myelome & SGFM Thalidomide as salvage therapy for relapsed multiple myeloma after allogeneic stem cell transplantation | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2601 | 0 | 0 | 2591 2004 BONE MARROW TRANSPLANTATION 33:S156-S157 Hardan I; Kneller A; Shimoni A; Berkowicz M; Avigdor A; Yeshurun M; Raanani P; Davidowich Y; Shemtov N; Ben Bassat I; Nagler A Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation | 0 | 0 |
2602 | 0 | 0 | 2592 2004 BONE MARROW TRANSPLANTATION 33:S160-S161 Ciepluch H; Knopinska-Posluszny W; Czyz J; Hellmann A Employment of autologous transplantation of progenitor cells following effective treatment with thalidomide of patients with multiple myeloma resistant to conventional chemotherapy | 0 | 0 |
2603 | 0 | 0 | 2593 2004 BONE MARROW TRANSPLANTATION 33:S161-S161 Trojan A; Giger R; Rist N; Jager D; Taverna C Thalidomide stimulates peptide specific CD8+T-cells against viral epitopes | 0 | 0 |
2604 | 0 | 0 | 2594 2004 BONE MARROW TRANSPLANTATION 33:S162-S162 Hoyer B; Fenk R; Steidl U; Germing U; Haas R; Kobbe G Treatment of patients with multiple myeloma in first relapse after high-dose chemotherapy with single agent thalidomide - duration of first remission is the major prognostic factor for EFS and OS | 0 | 0 |
2605 | 0 | 0 | 2595 2004 BONE MARROW TRANSPLANTATION 33:S165-S165 Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Mele A; Galieni P; Centurioni R; Alesiani F; Candela M; Leoni P Combination thalidomide, doxil and dexamethasone as salvage therapy for patients relapsed after tandem autotransplant | 0 | 0 |
2606 | 0 | 0 | 2596 2004 BONE MARROW TRANSPLANTATION 33:S356-S356 Alegre A; Martinez-Chamorro C; Escudero A; Aguado B; Osorio S; Nistal S; Cordoba R; Gil-Fernandez J; Sanchez-Godoy P; Burgaleta C; Casado F; Fernandez-Ranada JM Maintenance treatment with bisphosphonates plus interferon plus dexamethasone plus thalidomide (quadruple maintenance) after autologous peripheral blood stem cell transplantion in multiple myeloma: preliminary results | 0 | 0 |
2607 | 3 | 38 | 2597 2004 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 37(4):485-492 Arruda MSP; Richini VB; Oliveira SMA; Vilani-Moreno FR Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide-treated mice | 0 | 0 |
2608 | 0 | 0 | 2599 2004 BRITISH JOURNAL OF HAEMATOLOGY 125:20-20 Morris TCM; Hull DR; Boyd C; Jones FCG; Kettle PJ; Drake M; McLoughlin R; Quinn J Clarithromycin, dexamethasone and low dose thalidomide (CDT) is effective therapy in relapsed/refractory myeloma and useful in patients with cytopenias | 0 | 0 |
2609 | 4 | 5 | 2600 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(1):96-97 Fakhouri F; Guerraoui H; Presne C; Peltier J; Delarue R; Muret P; Knebelmann B Thalidomide in patients with multiple myeloma and renal failure | 0 | 0 |
2610 | 11 | 15 | 2601 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(2):149-155 Waage A; Gimsing P; Juliusson G; Turesson I; Gulbrandsen N; Eriksson T; Hjorth M; Nielsen JL; Lenhoff S; Westin J; Wisloff F; Nordic Myeloma Study Grp Early response predicts thalidomide efficiency in patients with advanced multiple myeloma | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2611 | 15 | 15 | 2602 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(2):101-104 Hershfield NB Disappearance of Chron's ulcers in the terminal ileum after thalidomide therapy | 0 | 0 |
2612 | 2 | 3 | 2603 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Cohen LB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. | 0 | 0 |
2613 | 0 | 0 | 2604 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Hershfield NB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. Response | 0 | 0 |
2614 | 7 | 8 | 2605 2004 CANCER 100(6):1186-1189 Pro B; Younes A; Albitar M; Dang NH; Samaniego F; Romaguera J; McLaughlin P; Hagemeister FB; Rodriguez MA; Clemons M; Cabanillas F Thalidomide for patients with recurrent lymphoma | 0 | 0 |
2615 | 5 | 17 | 2609 2004 CHIRALITY 16:S36-S39 Nakanishi T; Yamakawa N; Asahi T; Shibata N; Ohtani B; Osaka T Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality | 0 | 0 |
2616 | 2 | 13 | 2610 2004 CLINICAL AND EXPERIMENTAL DERMATOLOGY 29(3):268-270 Eisman S; Orteu CH Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment | 0 | 0 |
2617 | 10 | 20 | 2611 2004 CLINICAL CANCER RESEARCH 10(12):4192-4197 Ng SSW; Macpherson GR; Gutschow M; Eger K; Figg WD Antitumor effects of thalidomide analogs in human prostate cancer Xenografts implanted in immunodeficient mice | 0 | 0 |
2618 | 3 | 23 | 2612 2004 CLINICAL NEPHROLOGY 61(5):352-356 Menegato MA; Canelles MF; Tonutti E; Pizzolitto S Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease | 0 | 0 |
2619 | 52 | 65 | 2613 2004 CLINICAL PHARMACOKINETICS 43(5):311-327 Teo SK; Colburn WA; Tracewell WG; Kook KA; Stirling DI; Jaworsky MS; Scheffler MA; Thomas SD; Laskin OL Clinical pharmacokinetics of thalidomide | 0 | 0 |
2620 | 10 | 29 | 2614 2004 CYTOKINE 26(4):145-148 Rosinol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Blade J; Montserrat E Response to thalidomide in multiple myeloma: impact of angiogenic factors | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2621 | 12 | 17 | 2615 2004 DERMATOLOGY 208(2):149-152 Sander CS; Kaatz M; Elsner P Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide | 0 | 0 |
2622 | 1 | 1 | 2616 2004 DIABETOLOGIA 47(5):963-963 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats (vol 46, pg 1669, 2003) | 0 | 0 |
2623 | 8 | 28 | 2617 2004 DRUGS OF THE FUTURE 29(4):383-391 Hashimoto Y; Tanatani A; Nagasawa K; Miyachi H Thalidomide as a multitarget drug and its application as a template for drug design | 0 | 0 |
2624 | 24 | 52 | 2618 2004 DRUGS OF TODAY 40(3):197-204 Joglekar S; Levin M The promise of thalidomide: Evolving indications | 0 | 0 |
2625 | 16 | 28 | 2619 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(1):52-57 Strupp C; Germing U; Scherer A; Kundgen A; Modder U; Gattermann N; Haas R Thalidomide for the treatment of idiopathic myelofibrosis | 0 | 0 |
2626 | 16 | 30 | 2620 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(6):403-409 Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy | 0 | 0 |
2627 | 11 | 26 | 2621 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 73(2):98-103 Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure | 0 | 0 |
2628 | 4 | 22 | 2622 2004 EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 21(4):465-469 Abraham MH Hydrogen bond and other descriptors for thalidomide and its N-alkyl analogs; prediction of physicochemical and biological properties | 0 | 0 |
2629 | 0 | 37 | 2623 2004 EXPERIMENTAL BRAIN RESEARCH 156(3):333-341 Stoeckel MC; Pollok B; Schnitzler A; Witte OW; Seitz RJ Use-dependent cortical plasticity in thalidomide-induced upper extremity dysplasia: evidence from somaesthesia and neuroimaging | 0 | 0 |
2630 | 42 | 78 | 2624 2004 EXPERT OPINION ON THERAPEUTIC PATENTS 14(2):215-229 Luzzio FA; Figg WD Thalidomide analogues: derivatives of an orphan drug with diverse biological activity | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2631 | 0 | 0 | 2625 2004 FASEB JOURNAL 18(4):A68-A68 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide (Thd) decreases Fibronectin (FN)-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines | 0 | 0 |
2632 | 6 | 21 | 2626 2004 GUT 53(4):609-612 Bauditz J; Schachschal G; Wedel S; Lochs H Thalidomide for treatment of severe intestinal bleeding | 0 | 0 |
2633 | 7 | 25 | 2627 2004 HAEMATOLOGICA 89(5):552-556 Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma | 0 | 0 |
2634 | 19 | 37 | 2628 2004 HAEMATOLOGICA 89(7):826-831 Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; De Vivo A; Palareti G; Tura S; Baccarani M First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma | 0 | 0 |
2635 | 9 | 32 | 2629 2004 HAEMATOLOGICA 89(7):832-836 Rosinol L; Cibeira T; Blade J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E Extramedullary multiple myeloma escapes the effect of thalidomide | 0 | 0 |
2636 | 8 | 24 | 2630 2004 HISTOCHEMISTRY AND CELL BIOLOGY 122(1):27-33 Fujita K; Asami Y; Tanaka K; Akita M; Merker HJ Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta | 0 | 0 |
2637 | 5 | 30 | 2631 2004 INTERNATIONAL JOURNAL OF CANCER 110(2):260-265 Kedar I; Mermershtain W; Ivgi H Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy | 0 | 0 |
2638 | 17 | 25 | 2632 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(3):283-288 Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y Thalidomide-induced severe neutropenia during treatment of multiple myeloma | 0 | 0 |
2639 | 9 | 19 | 2633 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(4):364-368 Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells | 0 | 0 |
2640 | 13 | 26 | 2634 2004 JOURNAL OF CHILD NEUROLOGY 19(4):250-257 Schoeman JF; Springer P; van Rensburg AJ; Swanevelder S; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2641 | 8 | 24 | 2635 2004 JOURNAL OF CLINICAL ONCOLOGY 22(3):424-431 Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial | 0 | 0 |
2642 | 9 | 42 | 2636 2004 JOURNAL OF CLINICAL ONCOLOGY 22(13):2532-2539 Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer | 0 | 0 |
2643 | 0 | 1 | 2637 2004 JOURNAL OF CLINICAL ONCOLOGY 22(14):2973-2973 Kumar Thalidomide: Current role in the treatment of non-plasma cell malignancies (vol 22, pg 2477, 20040 | 0 | 0 |
2644 | 25 | 42 | 2638 2004 JOURNAL OF IMMUNOLOGY 172(8):5103-5109 Gockel HR; Lugering A; Heidemann J; Schmidt M; Domschke W; Kucharzik T; Lugering N Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway | 0 | 0 |
2645 | 8 | 18 | 2639 2004 JOURNAL OF IMMUNOTHERAPY 27(4):259-264 Elaraj DM; White DE; Steinberg SM; Haworth K; Rosenberg SA; Yang JC A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma | 0 | 0 |
2646 | 0 | 0 | 2640 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 122(3):A7-A7 Jin JH; Zhang W; Werth VP Thalidomide inhibits the induction of tumor necrosis factor-alpha by ultraviolet B irradiation of human keratinocytes | 0 | 0 |
2647 | 0 | 0 | 2641 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 123(2) Heere-Ress E; Boehm J; Hoeller C; Wacheck V; Thallinger C; Wolff K; Jansen B; Pehamberger H Thalidomide combined with dacarbazine enhances the anti-tumor activity in a human melanoma xenotransplantation model | 0 | 0 |
2648 | 0 | 0 | 2642 2004 JOURNAL OF INVESTIGATIVE MEDICINE 52(2):S403-S403 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide decreases fibronectin-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines. | 0 | 0 |
2649 | 15 | 23 | 2643 2004 JOURNAL OF MEDICINAL CHEMISTRY 47(9):2219-2227 Lepper ER; Ng SSW; Gutschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors | 0 | 0 |
2650 | 6 | 26 | 2644 2004 JOURNAL OF NEURO-ONCOLOGY 66(3):295-299 Piribauer M; Czech T; Dieckmann K; Birner P; Hainfellner JA; Prayer D; Fazeny-Dorner B; Weinlander G; Marosi C Stabilization of a progressive hemangioblastoma under treatment with thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2651 | 8 | 30 | 2645 2004 JOURNAL OF NEURO-ONCOLOGY 67(1-2):191-200 Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme | 0 | 0 |
2652 | 7 | 34 | 2646 2004 JOURNAL OF PERIODONTOLOGY 75(1):162-168 Lima V; Vidal FDP; Rocha FAC; Brito GAC; Ribeiro RA Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats | 0 | 0 |
2653 | 20 | 27 | 2647 2004 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310(2):571-577 Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans | 0 | 0 |
2654 | 27 | 45 | 2648 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(2):235-241 Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbe C; Morel P; Rybojad M Treatment of cutaneous sarcoidosis with thalidomide | 0 | 0 |
2655 | 0 | 0 | 2649 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(3):P78-P78 Wu JJ; Pang KR; Hsu S; Tyring SK Thalidomide: A review of new indications | 0 | 0 |
2656 | 13 | 23 | 2650 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(1):126-131 Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients | 0 | 0 |
2657 | 0 | 0 | 2651 2004 JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION 11(2):275A-275A Dharia SP; Steinkampf MP; Parker CR; Grubbs CJ; Crockett S The impact of thalidomide on ovarian function. | 0 | 0 |
2658 | 6 | 33 | 2652 2004 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2(2):327-334 Kaushal V; Kaushal GP; Melkaveri SN; Mehta P Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology | 0 | 0 |
2659 | 3 | 5 | 2653 2004 LANCET 363(9403):169-169 McBride W Health of thalidomide victims and their progeny | 0 | 0 |
2660 | 132 | 159 | 2654 2004 LANCET 363(9423):1802-1811 Franks ME; Macpherson GR; Figg WD Thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2661 | 2 | 5 | 2655 2004 LANCET 363(9424):1911-1911 Crawford CL Does thalidomide have a role in leprosy? | 0 | 0 |
2662 | 10 | 18 | 2658 2004 LEUKEMIA & LYMPHOMA 45(1):113-116 Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA Discordant response or progression in patients with myeloma treated with thalidomide-based regimens | 0 | 0 |
2663 | 4 | 13 | 2659 2004 LEUKEMIA & LYMPHOMA 45(1):179-181 Baird R; van Zyl-Smit RN; Iveson A; Duddy J; Rassam S Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia | 0 | 0 |
2664 | 14 | 20 | 2660 2004 LEUKEMIA & LYMPHOMA 45(4):735-738 Balleari E; Ghio R; Falcone A; Musto P Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases | 0 | 0 |
2665 | 7 | 12 | 2661 2004 LEUKEMIA & LYMPHOMA 45(8):1711-1712 Montagut C; Bosch F; Villela L; Rosinol L; Blade J Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide | 0 | 0 |
2666 | 15 | 59 | 2662 2004 LEUKEMIA RESEARCH 28(4):325-332 Musto P Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives | 0 | 0 |
2667 | 1 | 41 | 2663 2004 LEUKEMIA RESEARCH 28(8):791-803 Raza A; Buonamici S; Lisak L; Tahir S; Li DL; Imran M; Chaudary NI; Pervaiz H; Gallegos JA; Alvi MI; Mumtaz M; Gezer S; Venugopal P; Reddy P; Galili N; Candoni A; Singer J; Nucifora G Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression | 0 | 0 |
2668 | 5 | 7 | 2664 2004 LUPUS 13(6):481-482 Pagnoux C; Lutz-Zarrouk V; Michel M; Schaeffer A; Godeau B Cerebral venous thrombosis in a patient with antiphospholipid syndrome treated with thalidomide | 0 | 0 |
2669 | 15 | 44 | 2665 2004 MAYO CLINIC PROCEEDINGS 79(7):857-858 Silver RT Myelofibrosis: Thalidomide finds a new disease | 0 | 0 |
2670 | 12 | 22 | 2666 2004 MAYO CLINIC PROCEEDINGS 79(7):875-882 Richardson P; Schlossman R; Jagannath S; Alsina M; Desikan R; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Knight R; Zeldis J; Dalton W; Anderson K Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label Multicenter phase 2 study of efficacy, toxicity, and biological activity | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2671 | 59 | 83 | 2668 2004 MAYO CLINIC PROCEEDINGS 79(7):899-903 Rajkumar SV Thalidomide: Tragic past and promising future | 0 | 0 |
2672 | 0 | 2 | 2669 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):199-200 Crawford CL Licensing thalidomide in Australia | 0 | 0 |
2673 | 0 | 3 | 2670 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):200-200 Tattersall MHN Licensing thalidomide in Australia - Reply | 0 | 0 |
2674 | 5 | 5 | 2671 2004 MEDICAL JOURNAL OF AUSTRALIA 180(7):366-367 Coutsouvelis J; Corallo CE Thalidomide-induced bradycardia and its management | 0 | 0 |
2675 | 7 | 10 | 2672 2004 MEDICINA CLINICA 122(15):595-596 Cistero B; Sala M; Soler A; Garcia N Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient | 0 | 0 |
2676 | 10 | 32 | 2673 2004 MELANOMA RESEARCH 14(1):57-62 Pawlak WZ; Legha SS Phase II study of thalidomide in patients with metastatic melanoma | 0 | 0 |
2677 | 9 | 15 | 2674 2004 MICROCHEMICAL JOURNAL 77(1):1-7 Cardoso CE; Martins ROR; Aucelio RQ Evaluation of a spectrofluorimetric method for the selective determination of thalidomide in pharmaceutical tablets, urine and blood serum | 0 | 0 |
2678 | 21 | 45 | 2675 2004 MOLECULES AND CELLS 17(2):210-216 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on the stimulation of NF-kappa B activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line | 0 | 0 |
2679 | 15 | 16 | 2677 2004 NEUROLOGY 62(12):2158-2159 Apfel SC; Zochodne DW Thalidomide neuropathy - Too much or too long? | 0 | 0 |
2680 | 14 | 27 | 2680 2004 ONCOLOGY REPORTS 11(1):93-95 Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2681 | 14 | 24 | 2681 2004 ONKOLOGIE 27(2):150-154 Steurer M; Spizzo G; Mitterer M; Gastl G Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program | 0 | 0 |
2682 | 11 | 41 | 2682 2004 PATHOLOGY INTERNATIONAL 54(5):285-294 Du WL; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment | 0 | 0 |
2683 | 13 | 19 | 2683 2004 THROMBOSIS AND HAEMOSTASIS 91(4):834-836 Potenza L; Luppi M; Morselli M; Saviola A; Ferrari A; Riva G; Longo G; Marietta M; Torelli G Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making | 0 | 0 |
2684 | 2 | 10 | 2684 2004 TRANSPLANTATION PROCEEDINGS 36(4):1018-1020 Chaves DNB; Petroianu A; Alberti LR; Pereira WA Effects of thalidomide, cyclosporine, and diclofenac on skin allograft survival in rabbits | 0 | 0 |
2685 | 14 | 32 | 2685 2004 UROLOGY 63(6):1061-1065 Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma | 0 | 0 |
Page 9: 1 2 3 4 5 6 7 8 9
Generated by:
HistCite(Vlad).
Version: 2004.09.22